Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy

Clinical Colorectal Cancer

Volumn 2, Issue 4, 2003, Pages 231-234

  Yuste, Ana L ^a   Aparicio, Jorge ^a   Segura, Angel ^a   López Tendero, Pedro ^a   Gironés, Regina ^a   Pérez Fidalgo, José A ^a   Díaz, Roberto ^a   Calderero, Verónica ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Carcinoembryonic antigen; Hepatic function markers; Mayo Clinic regimen; Tumor markers; Visceral metastases

Indexed keywords

ALKALINE PHOSPHATASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; TUMOR MARKER;

ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HYPOALBUMINEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; VISCERAL METASTASIS;

EID: 0037301511     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.004     Document Type: Article

References (28)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide [database online]. IARC CancerBase No. 5. Lyon, France: IARC Press; 2001. Limited version available at: http://www-dep.iarc.fr/globocan/globocan.htm. Updated March 2, 2001.
2. Moreno V, González JR, Soler M, et al. Cancer incidence estimation in Spain: period 1993-1996 [in Spanish]. Gac Sanit 2001; 15:380-388.
3. American Cancer Society. Cancer Facts and Figures 2002. Atlanta, GA: American Cancer Society, 2002.
4. Scheithauer W, Rosen H, Kornek GB, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752-755.
5. Glimelius B, Hoffman K, Graf W, et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer: the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994; 73:556-562.
6. Jonker DJ, Maroon JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000; 82:1789-1794.
7. Petrelli N, Douglas H, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7:1419-1426.
8. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
9. Van Cutsem E, Dicatio M, Wils J. Recent advances in the management of colorectal cancer. Eur J Cancer 2001; 37:2302-2309.
10. Chang AC, Steinberg SM, Culnane M, et al. Determinants of survival in patients with unresectable colorectal cancer liver metastasis. J Surg Oncol 1989; 40:245-251.
11. Graf W, Glimelius B, Pahlman L, et al. Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 1991; 27:1119-1123.
12. Graf W, Bergstrom R, Palhman L, et al. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 1994; 30A:453-457.
13. Stang R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343:1405-1410.
14. Edler D, Kressner U, Ragnhammar P, et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000; 6:488-492.
15. Diez M, Pollán M, Múguera JM, et al. Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma. Cancer 2000; 88:35-41.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 55:163-170.
18. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34:187-200.
19. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. Ann Surg 1992; 199:502-550.
20. Steinberg J, Erlichman C, Gadalla T, et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 1992; 28A:1817-1820.
21. Massacesi C, Norman A, Price T, et al. A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 2000; 36:2044-2052.
22. Köhne CH, Cunningham D, DiCostanzo F, et al. Clinical determinants of survival in patients with 5-FU based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308-317.
23. Wang WS, Fan FS, Hsich RK, et al. Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan. Jpn J Clin Oncol 1997; 27:174-179.
24. Thirion P, Wolmark N, Haddad E, et al. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol 1999; 10:1317-1320.
25. Fountzilas G, Gossios K, Zisiadis A, et al. Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovorin based chemotherapy. Med Pediatr Oncol 1996; 5:305-317.
26. Assersohn L, Norman A, Cunningham D, et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999; 79:1800-1805.
27. Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology 1999; 46:905-908.
28. Reiter W, Stieber P, Reuter C, et al. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20:5195-5198.